While there is general consensus that screening adults over age 50 for colorectal cancer (the second leading cause of death from cancer in the US) is a valuable preventive intervention, there is some uncertainty about screening strategies, partly because of the number of available technologies and other factors affecting choice of strategy and partly because of a lack of knowledge about the natural history of the disease. These uncertainties have led to similar confusion about the proper cost-effective analysis (CEA) models screening modules. This publication results from a workshop convened by the Institute of Medicine's National Cancer Policy Board in which five different research teams compared their chosen (CEA) models--the Harvard, Ladabaum, Miscan, Vanderbilt, and Vijan models--with the intention being to provide insights into the different structures and assumptions of the models and differences in analysis resulting from the models. The workshop also explored the current state of knowledge on the key inputs for the models and identified areas of further research. Annotation ©2006 Book News, Inc., Portland, OR (booknews.com)
1 Front Matter; 2 Workshop Summary; 3 References; 4 Appendix A Workshop
Agenda: Economic Models of Colorectal Cancer Screening in Average-Risk
Adults; 5 Appendix B Workshop Participants; 6 Appendix C Workshop Speaker and
Staff Biographies; 7 Appendix D Overview of Harvard Model--Karen M. Kuntz,
ScD; 8 Appendix E Description of the Laudabaum Colorectal Cancer Screening
Model--Uri Ladabaum, M.D., M.S; 9 Appendix F MISCAN-colon: An
Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve,
Ann Zauber, Gerrit van Oortmar, and Dik Habbema; 10 Appendix G The Vanderbilt
Colorectal Cancer Model--R.M. Ness, R.W. Klein, R.S. Dittus; 11 Appendix H
Overview of the Vijan Colorectal Cancer Screening Model--Sandeep Vijan, M.D.,
M.S; 12 Appendix I Cost-Effectiveness Analyses of Colorectal Cancer
Screening: Results from a Pre-conference Modeling Exercise--Michael Pignone,
M.D.,; 13 Appendix J Recent Findings on Test Performance--Brian P. Mulhall,
M.D., M.P.H; 14 Appendix K Cost Issues in Cost Effectiveness Modeling of
Colorectal Cancer Screening--Martin L. Brown, Ph.D; 15 Appendix L Current
Evidence on Compliance --Sally W. Vernon, M.A., Ph.D; 16 Appendix M Recent
Trends in Follow-up Surveillance in Medicare Beneficiaries--Todd Anderson,
M.S; 17 Appendix N Preliminary Results from CDC; 18 Appendix O Colorectal
Cancer Surveillance Testing After Polypectomy--Deborah Schrag, M.D., M.P.H;
19 Appendix P Natural History of Colorectal Adenomas and Cancer--T. R. Levin,
M.D; 20 Appendix Q CISNET-Cancer Intervention and Surveillance--Eric J.
(Rocky) Feuer, Ph.D
Michael Pignone, Louise Russell and Judith Wagner, Editors, Institute of Medicine and National Research Council
Biežāk uzdotie jautājumi par e-grāmatām